AFIB Hypertension Pulmonary 
CardiacWire
JANUARY 24, 2024
CardioSignal has already developed digital biomarkers for AFib and heart failure, while more solutions could be on the way for aortic stenosis, coronary artery disease, and pulmonary artery hypertension.
Dr. Smith's ECG Blog
MARCH 28, 2024
male with pertinent past medical history including Atrial fibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Bedside ultrasound showed volume depletion and no pulmonary edema. SVT with aberrancy?
Ken Grauer, MD
APRIL 13, 2024
NOTE: For more on ECG recognition of RVH and/or pulmonary hypertension ( re the qR pattern in lead V1 ) — See ECG Blog #234 and Blog #248.
Dr. Smith's ECG Blog
FEBRUARY 6, 2024
Q waves in association with RBBB are usually not seen in anterior leads unless there is pulmonary hypertension or anterior infarction. Other Arrhythmias ( PACs, PVCs, AFib, Bradycardia and AV conduction disorders — potentially lethal VT/VFib ). Sinus Tachycardia ( common in any trauma patient. ).
Dr. Smith's ECG Blog
JANUARY 5, 2020
AFib is the irregularly irregular rhythm that is most commonly confused with MAT — and , AFib is much, much, much more common than true MAT. Therefore — IF the single-lead rhythm strip that you are using for cardiac monitoring does not clearly show identifiable P waves — it will be EASY to mistake this rhythm for AFib.
Dr. Smith's ECG Blog
JULY 7, 2023
An old formal echo was found from 6 mo ago: Dilated right ventricle with septal flattening and estimated right ventricular systolic pressure of 70 mmHg (significant pulmonary hypertension). She ruled out for acute MI by troponins. See further discussion of R/S ratio greater than 1 in lead V1 by Ken below. What else?
Heart 2023 Conference
APRIL 20, 2022
(Harvard University Heart Letter) A clinical polygenic risk score test for diseases ranging from atrial fibrillation (AFib) to breast cancer was piloted by scientists. JACC: Asia) Lexaria Bioscience has announced that a CBD product beats a placebo in simulating acute pulmonary hypertension.
Expert insights. Personalized for you.
75 
Let's personalize your content